Apyx Medical Corp reported the first quarter ended March 31, 2026 results: revenue total revenue of $12.5 million, net income Net loss attributable to stockholders of $2.1 million, EPS $0.05 per share. Guidance raised.
“99.1) --- EX-99.1 2 ex_905122.htm EXHIBIT 99.1 ex_905122.htm EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2026 Financial Results • Reported total revenue of $12.5 million in the first quarter of 2026 primarily driven by 36% growth in the Surgical Aesthetics segment • Raised total revenue guidance for FY2026 to a range of $59.0 million to $60.0”
Governance Changes
Apyx Medical Corp: Removed Article EIGHTH from Certificate of Incorporation and replaced with 'intentionally omitted' (effective 2025-12-08).
“On December 8, 2025, the Company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Amendment.”
Shawn Roman was appointed as Chief Operating Officer at Apyx Medical Corp.
“following the prior announcement that it had appointed Shawn Roman as its Chief Operating Officer”
Shawn D. Roman was appointed as Chief Operating Officer at Apyx Medical Corp.
“On November 6, 2024, the Board appointed Shawn D. Roman as the Chief Operating Officer of the Company, effective immediately.”
Craig Swandal resigned as Director at Apyx Medical Corp.
“On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.”
Michael Geraghty resigned as Director at Apyx Medical Corp.
“On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.”
John Andres resigned as Director at Apyx Medical Corp.
“On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.”
Earnings Releases
Apyx Medical Corp reported year ending December 31, 2024 results: revenue $49.7 million to $52.9 million. Guidance reaffirmed.
“respectively . Full Year 2024 Financial Outlook: The Company is reaffirming its financial guidance for the year ending December 31, 2024: • Total revenue in the range of $49.7 million to $52.9 million, representing a decrease of approximately 5% to growth of approximately 1% year-over-year, compared to total revenue of $52.3 million for the year ended December”
Earnings Releases
Apyx Medical Corp reported first quarter ended March 31, 2024 results: revenue $10.2 million, net income $7.6 million, EPS $0.22 per share. Guidance reaffirmed.
“quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024 First Quarter 2024 Financial Summary : • Total revenue of $10.2 million, a decrease of 16% year-over-year. ◦ Advanced Energy revenue of $7.5 million, a decrease of 23% year-over-year. ◦ OEM revenue of $2.8 million, an increase of 14% year-over-year.”
Stavros Vizirgianakis was appointed as Director and Chairman of the Board at Apyx Medical Corp.
“On May 7, 2024, the Board appointed Mr. Vizirgianakis to serve as a director and Chairman of the Board, to fill the vacancy created by the retirement of Andrew Makrides.”
Andrew Makrides retired as Chairman of the Board at Apyx Medical Corp.
“On May 7, 2024, Andrew Makrides announced his retirement as a director and Chairman of the Board, effective on the same date.”
Earnings Releases
Apyx Medical Corp reported year ended December 31, 2023 results: revenue $52.3 million, net income Net loss attributable to stockholders of $18.7 million. Guidance initiated.
“or 59%, year-over-year. • Adjusted EBITDA loss of $4.7 million, an increase of $0.6 million, or 14%, year-over-year. Full Year 2023 Financial Summary : • Total revenue of $52.3 million, an increase of 18% year-over-year. ◦ Advanced Energy revenue of $43.4 million, an increase of 18% year-over-year. ◦ OEM revenue of $9.0 million, an increase of 16%”
Earnings Releases
Apyx Medical Corp reported three months ended December 31, 2023 results: revenue $14.7 million, net income Net loss attributable to stockholders of $9.6 million.
“full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024. Fourth Quarter 2023 Financial Summary : • Total revenue of $14.7 million, an increase of 16% year-over-year. ◦ Advanced Energy revenue of $12.1 million, an increase of 15% year-over-year. ◦ OEM revenue of $2.5 million, an increase of 22%”
Earnings Releases
Apyx Medical Corp reported the year ended December 31, 2023 results: revenue $51.9 to $52.3 million.
“Total revenue in a range of $51.9 to $52.3 million, representing growth of 17% to 18% year-over-year.”
Earnings Releases
Apyx Medical Corp reported the fourth quarter ended December 31, 2023 results: revenue $14.2 to $14.6 million.
“Total revenue in a range of $14.2 to $14.6 million, representing growth of 13% to 16% year-over-year.”
Matthew Hill was appointed as Chief Financial Officer at Apyx Medical Corp.
“On November 28, 2023, Apyx Medical Corporation (the “Company”) announced that it had appointed Matthew Hill as its Chief Financial Officer, effective December 4, 2023 (the “Effective Date”).”
Tara Semb resigned as Chief Financial Officer at Apyx Medical Corp.
“On November 9, 2023, Apyx Medical Corporation (the “Company”) and Tara Semb, Chief Financial Officer, announced that Ms. Semb would be leaving the Company in order to pursue other opportunities.”
Debt Financings
Apyx Medical Corp incurred term loan of $37.5 million with Perceptive Credit Holdings IV, LP at floating rate based on one-month SOFR, subject to a floor of 5.0%, plus 7.0% maturing November 8, 2028.
“holly-owned subsidiaries (as subsidiary guarantors), and Perceptive Credit Holdings IV, LP (“Perceptive”) (as initial lender and administrative agent).”
Material Agreements
Apyx Medical Corp terminated Credit, Security and Guaranty Agreement with MidCap Funding IV Trust and MidCap Financial Trust (effective 2023-11-08).
“In connection with the Company’s execution of the Perceptive Credit Agreement, the Company (i) repaid all outstanding obligations under its prior Credit, Security and Guaranty Agreement, with MidCap Funding IV Trust and MidCap Financial Trust (the “MidCap Credit Agreement”) and (ii) terminated the MidCap Credit Agreement.”
Material Agreements
Apyx Medical Corp entered into Credit and Guaranty Agreement with Perceptive Credit Holdings IV, LP valued at up to $45 million (effective 2023-11-08).
“On November 8, 2023, Apyx Medical Corporation (the “Company”) entered into a Credit and Guaranty Agreement (the “Perceptive Credit Agreement”), by and among the Company (as borrower), Apyx China Holding Corp. and Apyx Bulgaria EOOD, the Company’s wholly-owned subsidiaries (as subsidiary guarantors), and Perceptive Credit Holdings IV, LP (“Perceptive”) (as initial lender and administrative agent).”
Earnings Releases
Apyx Medical Corp reported the third quarter ended September 30, 2023 results: revenue $12.0 million, net income Net loss attributable to stockholders of $4.6 million. Guidance reaffirmed.
“quarter ended September 30, 2023, and updated its financial expectations for the full year ending December 31, 2023. Third Quarter 2023 Financial Summary : • Total revenue of $12.0 million, up 31% year-over-year. ◦ Advanced Energy revenue of $9.8 million, up 39% year-over-year. ◦ OEM revenue of $2.1 million, up 5% year-over-year. • Net loss attributable to”
Shareholder Votes
Apyx Medical Corp shareholders approved Approval of the 2023 Share Incentive Plan at the 2023-08-10 meeting.
“Proposal 3: The Company’s stockholders approved the Company’s 2023 Share Incentive Plan by the following vote: Number of Votes Cast in Favor Number of Votes Cast Against Number of Votes Abstained 15,970,459 1,405,162 1,613,512”
Shareholder Votes
Apyx Medical Corp shareholders approved Ratification of RSM US LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-08-10 meeting.
“Proposal 2: The Company’s stockholders ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 by the following vote: Number of Votes Cast in Favor Number of Votes Cast Against Number of Votes Abstained 24,542,917 26,534 53,343”
Shareholder Votes
Apyx Medical Corp shareholders approved Election of eight directors at the 2023-08-10 meeting.
“On August 10, 2023, the following proposals were submitted to the stockholders of Apyx Medical Corporation (the “Company”) at its annual meeting of stockholders: (1) the election of eight (8) directors; (2) the ratification of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023; and (3) the approval of the Company’s 2023 Share Incentive Plan.”
Earnings Releases
Apyx Medical Corp reported second quarter ended June 30, 2023 results: revenue $13.6 million, net income Net loss attributable to stockholders of $1.0 million. Guidance reaffirmed.
“second quarter ended June 30, 2023, and reaffirms financial expectations for the full year ending December 31, 2023. Second Quarter 2023 Financial Summary : • Total revenue of $13.6 million, up 32% year-over-year. ◦ Advanced Energy revenue of $11.7 million, up 40% year-over-year. ◦ OEM revenue of $1.8 million, down 4% year-over-year. • Net loss attributable to”
Earnings Releases
Apyx Medical Corp reported the first quarter ended March 31, 2023 results: revenue $12.1 million, net income Net loss attributable to stockholders of $3.5 million. Guidance raised.
“its first quarter ended March 31, 2023, and updated financial expectations for the full year ending December 31, 2023. First Quarter 2023 Financial Summary : • Total revenue of $12.1 million, down 3% year-over-year. ◦ Advanced Energy revenue of $9.7 million, down 10% year-over-year. ◦ OEM revenue of $2.5 million, up 46% year-over-year. • Net loss attributable to”
Material Agreements
Apyx Medical Corp amended First Amendment to Purchase and Sale Agreement with VK Acquisitions VI, LLC (effective 2023-04-13).
“First Amendment to Purchase and Sale Agreement, dated April 12, 2023 : As previously reported by Apyx Medical Corporation (the “Company”) in a Current Report on Form 8-K filed with the Securities and Exchange Commission on March 15, 2023, on March 14, 2023 the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. Pursuant to the terms of the Purchase Agreement, the Purchaser initially had thirty (30) days from the date of execution to complete its satisfactory due diligence of the Property (the “Inspection Period”), during which time the Purchaser retained the right to cancel the Purchase Agreement. The initial closing of the transaction was to be held five (5) days following the expiration of the Inspection Pe”
Earnings Releases
Apyx Medical Corp reported full year ended December 31, 2022 results: revenue $44.5 million, net income Net loss attributable to stockholders of $23.2 million. Guidance initiated.
“the fourth quarter of 2021. • Adjusted EBITDA loss of $4.1 million, compared to $0.3 million for the fourth quarter of 2021. Full Year 2022 Financial Summary: • Total revenue of $44.5 million, down 8% year-over-year. ◦ Advanced Energy revenue of $36.8 million, down 14% year-over-year. ◦ OEM revenue of $7.7 million, up 39% year-over-year. • Net loss attributable to”
Earnings Releases
Apyx Medical Corp reported for the fourth quarter and year ended December 31, 2022 results: revenue $12.6 million, net income Net loss attributable to stockholders of $6.0 million.
“full year ended December 31, 2022, and introduced financial expectations for the full year ending December 31, 2023. Fourth Quarter 2022 Financial Summary : • Total revenue of $12.6 million, down 25% year-over-year. ◦ Advanced Energy revenue of $10.5 million, down 30% year-over-year. ◦ OEM revenue of $2.1 million, up 15% year-over-year. • Net loss attributable to”
Material Agreements
Apyx Medical Corp entered into Single Tenant Industrial Building Lease with VK Acquisitions VI, LLC valued at $619,500 for the first year (effective 2023-03-14).
“On March 14, 2023, Apyx Medical Corporation (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000.”
Debt Financings
Apyx Medical Corp incurred revolving credit of up to $10 million with MidCap Funding IV Trust at Adjusted Term SOFR, subject to a floor of 2.5%, plus 4% maturing February 1, 2028.
“The secured revolving facility provides for loans in an aggregate principal amount of up to $10 million”
Debt Financings
Apyx Medical Corp incurred term loan of $10 million with MidCap Funding IV Trust at Adjusted Term SOFR, subject to a floor of 2.5%, plus 7.35% maturing February 1, 2028.
“17, 2023, Apyx Medical Corporation (the “Company”) entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”), by and among the Company (as borrower) and Apyx China Holding Corp., the Company’s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time.”
Material Agreements
Apyx Medical Corp entered into Credit, Security and Guaranty Agreement with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto valued at up to $35 million (effective 2023-02-17).
“On February 17, 2023, Apyx Medical Corporation (the “Company”) entered into a Credit, Security and Guaranty Agreement (the “Credit Agreement”), by and among the Company (as borrower) and Apyx China Holding Corp., the Company’s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time. The Credit Agreement provides for an up to $35 million facility”
Earnings Releases
Apyx Medical Corp reported preliminary financial results for the quarter and year ended December 31, 2022.
“On January 10, 2023, Apyx Medical Corporation (the "Company") issued a press release reporting on its preliminary revenue results for the quarter and year ended December 31, 2022.”
Earnings Releases
Apyx Medical Corp reported third quarter ended September 30, 2022 results: revenue $9.1 million, net income Net loss attributable to stockholders of $5.8 million. Guidance reaffirmed.
“third quarter ended September 30, 2022, and updated financial expectations for the full year ending December 31, 2022. Third Quarter 2022 Financial Summary : • Total revenue of $9.1 million, down 23% year-over-year. ◦ Advanced Energy revenue of $7.1 million, down 31% year-over-year. ◦ OEM revenue of $2.0 million, up 34% year-over-year. • Net loss attributable to”
Wendy Levine was appointed as Director at Apyx Medical Corp.
“On August 24, 2021, the Board of Direct ors (the “Board”) of Apyx Medical Corporation (the “Company”) appointed Wendy Levine to serve as a director of the Company, expanding its Board to eight (8) directors, effective August 25, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.